Shattuck Labs, Inc. (STTK)
NASDAQ:STTK
Want to see STTK full AI Analyst Report?
Top Page
Shattuck Labs
(NASDAQ:STTK)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.00
▼(-33.60% Downside)
Action:Reiterated
Date:06/03/26
The score is driven primarily by weak financial performance (large losses on minimal revenue and ongoing cash burn), partially cushioned by a low-leverage balance sheet. Technicals also weigh on the score due to a bearish trend and negative MACD, while valuation is constrained by negative earnings and no dividend. Governance-related corporate events are a mild positive but not a fundamental catalyst.
Positive Factors
Proprietary ARC platform and pipeline
The ARC platform and multi-functional biologics approach represent a structural R&D advantage: a technology-led pipeline can create differentiated molecules and multiple clinical programs. Over months this underpins long-term value creation if clinical data validate the mechanism and enable partnerships or licensing.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow indicates the company is funding operations via cash or financing rather than internal generation. Over 2–6 months this elevates dilution and financing risk, pressuring management to secure capital or partnerships before runway tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ARC platform and pipeline
The ARC platform and multi-functional biologics approach represent a structural R&D advantage: a technology-led pipeline can create differentiated molecules and multiple clinical programs. Over months this underpins long-term value creation if clinical data validate the mechanism and enable partnerships or licensing.
Read all positive factors
Shattuck Labs (STTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$373.43M
Dividend YieldN/A
Average Volume (3M)552.47K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue Growth-78.29%
EPS Growth54.16%
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.63
Shares Outstanding76,680,520
10 Day Avg. Volume595,526
30 Day Avg. Volume552,473
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue196.64
Enterprise Value/Gross Profit-239.81
Enterprise Value/Ebitda-4.11
Forecast
1Y Price Target
$13.00Price Target Upside72.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Shattuck Labs Business Overview & Revenue Model
Company Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for t...
How the Company Makes Money
null...
Shattuck Labs Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00M | 1.00M | 5.72M | 1.66M | 652.00K | 30.02M |
| Gross Profit | -820.00K | 1.00M | 5.72M | -2.38M | 652.00K | 28.64M |
| EBITDA | -47.79M | -47.82M | -76.74M | -87.92M | -100.26M | -43.89M |
| Net Income | -49.87M | -48.81M | -75.41M | -87.30M | -101.94M | -44.97M |
Balance Sheet | ||||||
| Total Assets | 102.12M | 91.03M | 91.05M | 159.56M | 205.32M | 298.58M |
| Cash, Cash Equivalents and Short-Term Investments | 90.42M | 78.06M | 72.99M | 130.63M | 161.28M | 268.80M |
| Total Debt | 2.04M | 1.58M | 3.41M | 4.20M | 4.90M | 0.00 |
| Total Liabilities | 6.29M | 8.64M | 11.42M | 14.86M | 29.17M | 26.80M |
| Stockholders Equity | 95.83M | 82.39M | 79.63M | 144.71M | 176.16M | 271.79M |
Cash Flow | ||||||
| Free Cash Flow | -41.28M | -39.95M | -60.57M | -81.64M | -106.11M | -65.04M |
| Operating Cash Flow | -41.27M | -39.88M | -60.52M | -81.23M | -94.50M | -57.12M |
| Investing Cash Flow | 361.00K | -7.89M | -8.51M | 110.86M | 49.44M | -10.44M |
| Financing Cash Flow | 70.43M | 44.57M | 787.00K | 48.62M | 171.00K | 1.93M |
Shattuck Labs Technical Analysis
Negative
7.53
Price Trends
6.63
Negative
5.63
Negative
3.94
Positive
Market Momentum
-0.40
Positive
24.96
Positive
3.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Negative. The current price of 7.53 is above the 20-day moving average (MA) of 6.13, above the 50-day MA of 6.63, and above the 200-day MA of 3.94, indicating a neutral trend. The MACD of -0.40 indicates Positive momentum. The RSI at 24.96 is Positive, neither overbought nor oversold. The STOCH value of 3.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STTK.
Shattuck Labs Risk Analysis
Shattuck Labs disclosed 56 risk factors in its most recent earnings report. Shattuck Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shattuck Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $92.94M | -3.08 | -241.96% | ― | ― | 55.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $49.06M | -42.54 | -117.24% | ― | 476.71% | 70.23% | |
50 Neutral | $67.20M | -0.76 | -64.43% | ― | ― | 9.80% | |
46 Neutral | $373.43M | -10.69 | -60.73% | ― | -78.29% | 54.16% |
* Healthcare Sector Average
STTK
Shattuck Labs
4.75
3.59
309.48%
PYPD
PolyPid
4.72
1.74
58.39%
XLO
Xilio Therapeutics
8.15
-1.18
-12.63%
ACRV
Acrivon Therapeutics, Inc.
1.51
0.28
22.76%
Shattuck Labs Corporate Events
Executive/Board ChangesShareholder Meetings
Shattuck Labs Shareholders Approve Directors, Compensation, Governance Measures
Positive
Jun 2, 2026
At its recent Annual Meeting, Shattuck Labs’ shareholders elected all Class III director nominees, including Taylor Schreiber, M.D., Ph.D., Helen M. Boudreau and Clay Siegall, Ph.D., and approved all other proposals, including the ratificati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.